480 related articles for article (PubMed ID: 26825231)
1. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
[TBL] [Abstract][Full Text] [Related]
2. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
[TBL] [Abstract][Full Text] [Related]
3. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.
Ali ZA; Gao R; Kimura T; Onuma Y; Kereiakes DJ; Ellis SG; Chevalier B; Vu MT; Zhang Z; Simonton CA; Serruys PW; Stone GW
Circulation; 2018 Jan; 137(5):464-479. PubMed ID: 29089314
[TBL] [Abstract][Full Text] [Related]
4. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
Gao R; Yang Y; Han Y; Huo Y; Chen J; Yu B; Su X; Li L; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Xu B; Popma JJ; Stone GW;
J Am Coll Cardiol; 2015 Dec; 66(21):2298-2309. PubMed ID: 26471805
[TBL] [Abstract][Full Text] [Related]
5. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
Stone GW; Ellis SG; Gori T; Metzger DC; Stein B; Erickson M; Torzewski J; Williams J; Lawson W; Broderick TM; Kabour A; Piegari G; Cavendish J; Bertolet B; Choi JW; Marx SO; Généreux P; Kereiakes DJ;
Lancet; 2018 Oct; 392(10157):1530-1540. PubMed ID: 30266412
[TBL] [Abstract][Full Text] [Related]
6. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
[TBL] [Abstract][Full Text] [Related]
7. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
[TBL] [Abstract][Full Text] [Related]
8. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
[TBL] [Abstract][Full Text] [Related]
9. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.
Stone GW; Kimura T; Gao R; Kereiakes DJ; Ellis SG; Onuma Y; Chevalier B; Simonton C; Dressler O; Crowley A; Ali ZA; Serruys PW
JAMA Cardiol; 2019 Dec; 4(12):1261-1269. PubMed ID: 31561250
[TBL] [Abstract][Full Text] [Related]
10. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
11. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
[TBL] [Abstract][Full Text] [Related]
12. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Sabate M; Cequier A; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Gómez-Hospital JA; Baz JA; Martin-Yuste V; van Geuns RJ; Alfonso F; Bordes P; Tebaldi M; Masotti M; Silvestro A; Backx B; Brugaletta S; van Es GA; Serruys PW
Lancet; 2012 Oct; 380(9852):1482-90. PubMed ID: 22951305
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
[TBL] [Abstract][Full Text] [Related]
14. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
[TBL] [Abstract][Full Text] [Related]
15. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial.
Xu B; Yang Y; Han Y; Huo Y; Wang L; Qi X; Li J; Chen Y; Kuo HC; Ying SW; Cheong WF; Zhang Y; Su X; Popma JJ; Gao R; Stone GW
EuroIntervention; 2018 Aug; 14(5):e554-e561. PubMed ID: 30082268
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
[TBL] [Abstract][Full Text] [Related]
17. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
[TBL] [Abstract][Full Text] [Related]
18. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
Kereiakes DJ; Ellis SG; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; Tan SH; Ediebah DE; Simonton C; Stone GW;
Circulation; 2019 Dec; 140(23):1895-1903. PubMed ID: 31553222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
